Peter Gavorník, Viera Fialová
Antiplatelet therapy by acetylsalicylic acid (ASA, aspirin) provided pivotal advances in the prevention and treatment of
organovascular (angiovascular, cardiovascular, cerebrovascular, extremitovascular, renovascular, genitovascular, mesenteriointestinokolonovascular,
bronchopulmovascular, oculovascular, otovascular and other) arterial ischemic diseases.
Currently available antiplatelet drugs have some limitations which might be overcomed by improved dosing regimens,
use of combination of agents affecting different platelet functions and, in particular, by the new antiplatelet
drugs (new arterial antithrombotics) with distinct pharmacodynamic properties offering new advantages, including faster
onset of action, greater potency, and reversibility of effects.